Investigational drug · Phase 3
HDM1005 1
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes, Obesity & Overweight.
Phase 3Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
11
Any phase or sponsor naming "HDM1005 1"
First trial start
2025
Apr 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HDM1005 1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
- Obesity & Overweight
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HDM1005 1" as an intervention, largest first.
- A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorPivotal-lookingNot yet recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07417306 · 912 participants (planned) · Start Mar 27, 2026 · Primary completion Aug 30, 2027
Drug: HDM1005 1; HDM1005 2 and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
- Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without DiabetesPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07279194 · 825 participants (planned) · Start Oct 14, 2025 · Primary completion Sep 20, 2026
Drug: HDM1005 1; HDM1005 2 and 1 more · For: Obesity & Overweight
Sites: Shanghai, China
- Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without DiabetesPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07521631 · 372 participants (planned) · Start Mar 31, 2026 · Primary completion Feb 4, 2027
Drug: HDM1005 dose level 1; HDM1005 dose level 2 and 2 more · For: Obesity
Sites: Shanghai, China
- A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AlonePivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07394114 · 240 participants (planned) · Start Feb 24, 2026 · Primary completion Aug 28, 2027
Drug: HDM1005 1; HDM1005 2 and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
- Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes MellitusPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06886126 · 240 participants (planned) · Start Feb 7, 2025 · Primary completion Sep 23, 2025
Drug: HDM1005 injection or placebo · For: Obesity
Sites: Nanjing, China
- A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07109700 · 216 participants (planned) · Start Apr 30, 2025 · Primary completion Jan 31, 2026
Drug: HDM1005 1; HDM1005 2 and 4 more · For: Type 2 Diabetes
Sites: Beijing, China
- A Pharmacokinetic Study of HDM1005 Injection at Different Injection SitesPivotal-lookingActive, not recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07828197 · 135 participants (planned) · Start Sep 3, 2026 · Primary completion Oct 2026
Drug: HDM1005 · For: Overweight and/or Obesity; Healthy Participants
Sites: Hefei, China
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06637020 · 80 participants · Start Jun 21, 2024 · Primary completion Mar 28, 2025
Drug: HDM1005 injection or placebo; HDM1005 injection or placebo · For: Overweight and Obesity
Sites: Hefei, China
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06640647 · 65 participants · Start Mar 19, 2024 · Primary completion Aug 6, 2024
Drug: HDM1005 injection or placebo · For: Obesity and Overweight
Sites: Hefei, China
- Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and DigoxinNot yet recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07502001 · 42 participants (planned) · Start Apr 8, 2026 · Primary completion Dec 1, 2026
Drug: Acetaminophen; Metformin and 4 more · For: Overweight; Obesity
Sites: Hefei, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.